MERKEL CELL CARCINOMA

This study tested a combination of two drugs, lenvatinib and pembrolizumab, given before surgery to people with Merkel cell carcinoma, a rare and aggressive skin cancer. The goal was to see if the drugs could shrink or eliminate the tumor before it was removed. The trial enrolled…

This study tests giving a short course of chemotherapy plus immunotherapy before surgery for people with Merkel cell carcinoma that can be removed. The goal is to see if this approach can completely eliminate the cancer in the removed tissue. About 36 adults with stage II or III …

This early-phase study tests a new treatment called BOXR1030, which uses specially designed immune cells to target a protein (GPC3) found on certain advanced solid tumors. The study involves 7 adults with liver, lung, skin, or soft tissue cancers that have not responded to standa…

This study tests a drug called RP1, which is injected directly into skin tumors, for people who have had an organ or stem cell transplant and now have advanced skin cancer. The goal is to see if RP1 can shrink tumors safely without harming the transplanted organ. About 69 partici…

This study tests whether adding targeted radiation to a two-drug immunotherapy combination works better than the drugs alone for people with advanced Merkel cell carcinoma, a rare and aggressive skin cancer. About 50 adults with stage IV or recurrent disease will receive either n…

This early-phase study tests a new form of the chemotherapy drug topotecan, wrapped in a liposome (a tiny fat bubble), to see if it is safe and tolerable for people with advanced solid tumors that have not responded to standard treatments. The study includes cancers like ovarian,…

This early-phase study tests whether 30 minutes of moderate exercise (like cycling or walking) right before standard immunotherapy can improve how well the treatment works against certain skin cancers. About 22 adults with melanoma, squamous cell carcinoma, or Merkel cell carcino…

This study is for people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease has progressed after standard immunotherapy. It tests a new drug combination designed to boost the immune system to fight cancer. About 40 participants will receive the experime…

This study tests a two-step treatment for people with rare skin cancers or certain lymphomas that haven't improved with standard care. First, patients receive a virus-based drug (talimogene laherparepvec) injected into tumors to help the immune system recognize and attack cancer …

This early-phase study tests whether a mix of drugs and targeted radiation can help the immune system recognize and attack hard-to-treat solid tumors. About 14 adults with advanced melanoma, breast cancer, or other solid cancers that cannot be surgically removed will receive inje…

This study tests whether giving targeted radiation therapy alongside the immunotherapy drug avelumab can help control Merkel cell carcinoma that has spread and is no longer responding to standard treatment. About 18 adults with advanced, inoperable cancer will receive this combin…

This study tests whether a combination of three immunotherapy drugs can shrink or control advanced Merkel cell carcinoma that has not responded to standard treatment. The drugs work by reactivating the immune system to fight the cancer. The trial involves 12 adults whose cancer h…

This study tests whether the immunotherapy drug avelumab can help prevent Merkel cell carcinoma from returning after initial treatment. About 122 adults with stage I to III Merkel cell carcinoma are randomly assigned to receive either avelumab or a placebo. The main goal is to se…

This early-stage study tests whether giving the drug cemiplimab before surgery is safe for people with Merkel cell carcinoma or cutaneous squamous cell carcinoma. About 36 participants will receive the drug and then have their tumors removed. Researchers will track side effects a…

This study tests a new type of PET/CT scan that uses a radioactive tracer called 68Ga-DOTATOC to find neuroendocrine tumors (NETs) and other related cancers. The scan targets a molecule found in high amounts on these tumor cells. Researchers want to see if this scan is safer and …

This small pilot study tests whether a short exercise session on the same day as immunotherapy can help patients with skin cancers like melanoma. Twelve adults scheduled for their first immunotherapy will walk for 20-30 minutes before treatment. The goal is to see if this is feas…